产品名称
Anti-PARP Poly ADP-ribose Polymerase-1 Antibody, serum, Chemicon®
biological source
rabbit
conjugate
unconjugated
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
species reactivity
rat, human, bovine, mouse
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Quality Level
Gene Information
bovine ... Parp1(286764)
human ... PARP1(142)
mouse ... Parp1(11545)
rat ... Parp1(25591)
Application
Research Category
Apoptosis & Cancer
Metabolism
Apoptosis & Cancer
Metabolism
Research Sub Category
Apoptosis - Additional
Enzymes & Biochemistry
Apoptosis - Additional
Enzymes & Biochemistry
This Anti-PARP Poly ADP-ribose Polymerase-1 Antibody is validated for use in ELISA, WB for the detection of PARP Poly ADP-ribose Polymerase-1.
Western blot: 1:500 using alkaline phosphatase.
ELISA
Optimal working dilutions must be determined by end user.
ELISA
Optimal working dilutions must be determined by end user.
Biochem/physiol Actions
Recognizes 116 kDa PARP-1 and the 85 kDa apoptosis-related cleavage fragment.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Immunogen
Synthetic peptide based on the sequence from the C-terminal portion of the bovine PARP automodification domain (amino acids 509-524) conjugated to a carrier.
Other Notes
Replaces: 04-575; 04-576
Physical form
Antiserum containing 0.05% sodium azide. Liquid containing 0.05% sodium azide.
Preparation Note
Maintain frozen at -20°C in undiluted aliquots for up to 12 months.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品?
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
Lauren K Jillson et al.
Molecular cancer research : MCR, 19(7), 1123-1136 (2021-04-14)
Prostate cancer genomic subtypes that stratify aggressive disease and inform treatment decisions at the primary stage are currently limited. Previously, we functionally validated an aggressive subtype present in 15% of prostate cancer characterized by dual deletion of MAP3K7 and CHD1.
Kwang Il Park et al.
Oncology letters, 13(4), 2521-2530 (2017-04-30)
Lonicera japonica Thunb. (L. japonica T.) has historically been used in Korean herbal medicine due to its anticancer and protective effects on the respiratory system. In the present study, the polyphenolic compounds in L. japonica T. were investigated using high-performance
Hypermethylated in cancer 1 (HIC1), a tumor suppressor gene epigenetically deregulated in hyperparathyroid tumors by histone H3 lysine modification.
Svedlund, J; Koskinen Edblom, S; Marquez, VE; ?kerstrom, G; Bjorklund, P; Westin, G
The Journal of clinical endocrinology and metabolism null
Marlena Zyśk et al.
International journal of molecular sciences, 21(22) (2020-11-18)
The N-acetylaspartate network begins in neurons with N-acetylaspartate production catalyzed by aspartate N-acetyltransferase from acetyl-CoA and aspartate. Clinical studies reported a significant depletion in N-acetylaspartate brain level in type 1 diabetic patients. The main goal of this study was to
Jessica Svedlund et al.
Endocrine-related cancer, 21(2), 231-239 (2013-12-03)
Primary hyperparathyroidism (pHPT) resulting from parathyroid tumors is a common endocrine disorder with incompletely understood etiology. In renal failure, secondary hyperparathyroidism (sHPT) occurs with multiple tumor development as a result of calcium and vitamin D regulatory disturbance. The aim of
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持